MGX: Metagenomi, Inc. Cash Funds Calculated per Share

Symbol and logo of brand Metagenomi Therapeutics (MGX)

Strict FDA oversight and patent protection create colossal barriers to entry for new players in the DNA therapy sector. Fluctuations in cash per share visualize the financial stability of Metagenomi, Inc. (MGX), with the current mark equal to 2.68. Metagenomi, Inc. (MGX) is actively engaging pharma behemoths in the joint search for treatments for rare pathologies, leveraging its own proprietary AI platform for genome editing.

Cash per Share: Metagenomi (MGX) for 02/21/2024 - 11/20/2026

Comprehensive metric breakdowns and analytics for Metagenomi, Inc (MGX)

- stock value and consensus price forecast:
- cash and cash flow data:
Comprehensive company analysis:Metagenomi, Inc MGX
Product sample of Metagenomi Inc.

Metagenomi, Inc. (MGX) invests in leading geneticists and the development of CRISPR technologies, which requires colossal operating expenses. This metric is calculated by dividing the total volume of liquid assets by the number of shares outstanding. The metric determines the business's financial cushion and the level of investor capital protection. High reserves guarantee survival but may indicate inefficient use of funds. The trend of current cash per share clearly demonstrates the balance between liquidity and investment activity.

Key competitors

TEM (Tempus AI Inc) - Cash Calculated per Single Share|Cash per Share QGEN|IONS - Cash on Hand per Share|Cash Funds per Share Repligen RGEN|RNA: Cash Funds per Single Share|CRSP: Cash per Single Share|GeneDx Corp (WGS) - Cash per Single Share|RARE: Cash per Share|BEAM - Cash Funds Calculated per Share|SRPT (Sarepta Therapeutics) - Cash per Share|Cash per Single Share Twist Bioscience Inc (TWST)|Cash per Share TXG|Cash Funds Calculated per Share Intellia|Stoke - Cash per Single Share|BLFS: Cash Funds per Single Share|Wave Life Sciences Corp - Cash per Share|Maze Therapeutics, Inc. (MAZE) - Cash per Single Share|Sionna Therapeutics Inc (SION) - Cash Funds per Share|Cash per Single Share Prime Medicine Corp|Cash Funds per Share tayshagtx.com|QURE - Cash Funds Volume per Share|Cash per Single Share MGTX (MeiraGTx Holdings plc)|REGENXBIO (RGNX) - Cash Funds Volume per Share|Cash per Share SLDB (Solid Biosciences Inc.)|Amount of Cash per Share OCGN|PacBio Corp - Cash per Share|Benitec Biopharma Inc. (BNTC) - Cash per Single Share|DSGN: Cash per Share|Cash Funds per Single Share RCKT|Cash per Single Share FDMT|Cash Funds per Single Share LXEO (Lexeo Therapeutics)|Cash per Share KRRO|Editas Medicine, Inc. - Cash Funds per Single Share|Cash Funds per Share Silence Therapeutics Inc. SLN|Cash per Share ProQR Therapeutics N.V. PRQR|CDXS: Cash per Single Share|Cash Funds Volume per Share Sangamo (SGMO)|NAUT (Nautilus Bio) - Cash per Single Share|Cash per Single Share Precision BioSciences, Inc.|GBIO (Generation Bio) - Cash per Share|Boundless Bio Inc. (BOLD) - Cash Funds Calculated per Share|Cash per Single Share XCUR (exicuretx.com)|Imunon Inc - Cash Funds per Single Share|Cash per Share PHIO (Phio Pharmaceuticals Corp)|Amount of Cash per Share MBIO|RNAZ - Cash Funds per Share|Amount of Cash per Share BNGO (bionanogenomics.com)|Applied DNA Sciences (APDN) - Cash Funds per Share|Bluebird Bio - Amount of Cash per Share|IPA (ImmunoPrecise Antibodies Ltd) - Cash per Share|Cash on Hand per Share Omega Therapeutics, Inc. OMGA|Cash per Share OMIC|RGLS (Regulus Therapeutics Inc.) - Amount of Cash per Share|Cash per Share SYRS (Syros Pharmaceuticals Inc.)|Cash Calculated per Single Share TBIO (Codex DNA)|TCON - Cash Funds per Share|Cash on Hand per Share Unity Biotechnology